Pharma & Healthcare
Global Tumor Immunotherapy Drugs Market Research Report 2025
- Jun 01, 25
- ID: 285999
- Pages: 93
- Figures: 90
- Views: 24
The global market for Tumor Immunotherapy Drugs was valued at US$ 50060 million in the year 2024 and is projected to reach a revised size of US$ 90180 million by 2031, growing at a CAGR of 8.9% during the forecast period.
Tumor immunotherapy refers to destroying cancer cells by stimulating and activating the patient"s own immune system.
North American market for Tumor Immunotherapy Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Tumor Immunotherapy Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Tumor Immunotherapy Drugs include Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences, Pfizer, Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Tumor Immunotherapy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Immunotherapy Drugs.
The Tumor Immunotherapy Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Tumor Immunotherapy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tumor Immunotherapy Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Bristol Myer Squibb
AstraZeneca
Merck
Roche / Genentech
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Pfizer, Inc
F. Hoffmann-La Roche Ltd
Incyte Corporation
NewLink Genetics Corporation
Celldex Therapeutics, Inc
GlaxoSmithKline
Segment by Type
Immune Checkpoint Inhibitors
Tumor Vaccine
Adoptive Immunotherapy
Non-specific Immunomodulator
Segment by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Tumor Immunotherapy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Tumor Immunotherapy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Tumor immunotherapy refers to destroying cancer cells by stimulating and activating the patient"s own immune system.
North American market for Tumor Immunotherapy Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Tumor Immunotherapy Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Tumor Immunotherapy Drugs include Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences, Pfizer, Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Tumor Immunotherapy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Immunotherapy Drugs.
The Tumor Immunotherapy Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Tumor Immunotherapy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tumor Immunotherapy Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Bristol Myer Squibb
AstraZeneca
Merck
Roche / Genentech
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Pfizer, Inc
F. Hoffmann-La Roche Ltd
Incyte Corporation
NewLink Genetics Corporation
Celldex Therapeutics, Inc
GlaxoSmithKline
Segment by Type
Immune Checkpoint Inhibitors
Tumor Vaccine
Adoptive Immunotherapy
Non-specific Immunomodulator
Segment by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Tumor Immunotherapy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Tumor Immunotherapy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Tumor Immunotherapy Drugs Market Overview
1.1 Product Definition
1.2 Tumor Immunotherapy Drugs by Type
1.2.1 Global Tumor Immunotherapy Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Tumor Vaccine
1.2.4 Adoptive Immunotherapy
1.2.5 Non-specific Immunomodulator
1.3 Tumor Immunotherapy Drugs by Application
1.3.1 Global Tumor Immunotherapy Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Tumor Immunotherapy Drugs Market Size Estimates and Forecasts
1.4.1 Global Tumor Immunotherapy Drugs Revenue 2020-2031
1.4.2 Global Tumor Immunotherapy Drugs Sales 2020-2031
1.4.3 Global Tumor Immunotherapy Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Tumor Immunotherapy Drugs Market Competition by Manufacturers
2.1 Global Tumor Immunotherapy Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Tumor Immunotherapy Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Tumor Immunotherapy Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Tumor Immunotherapy Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Tumor Immunotherapy Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Tumor Immunotherapy Drugs, Product Type & Application
2.7 Global Key Manufacturers of Tumor Immunotherapy Drugs, Date of Enter into This Industry
2.8 Global Tumor Immunotherapy Drugs Market Competitive Situation and Trends
2.8.1 Global Tumor Immunotherapy Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Tumor Immunotherapy Drugs Players Market Share by Revenue
2.8.3 Global Tumor Immunotherapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Tumor Immunotherapy Drugs Market Scenario by Region
3.1 Global Tumor Immunotherapy Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Tumor Immunotherapy Drugs Sales by Region: 2020-2031
3.2.1 Global Tumor Immunotherapy Drugs Sales by Region: 2020-2025
3.2.2 Global Tumor Immunotherapy Drugs Sales by Region: 2026-2031
3.3 Global Tumor Immunotherapy Drugs Revenue by Region: 2020-2031
3.3.1 Global Tumor Immunotherapy Drugs Revenue by Region: 2020-2025
3.3.2 Global Tumor Immunotherapy Drugs Revenue by Region: 2026-2031
3.4 North America Tumor Immunotherapy Drugs Market Facts & Figures by Country
3.4.1 North America Tumor Immunotherapy Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Tumor Immunotherapy Drugs Sales by Country (2020-2031)
3.4.3 North America Tumor Immunotherapy Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Tumor Immunotherapy Drugs Market Facts & Figures by Country
3.5.1 Europe Tumor Immunotherapy Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Tumor Immunotherapy Drugs Sales by Country (2020-2031)
3.5.3 Europe Tumor Immunotherapy Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Tumor Immunotherapy Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Tumor Immunotherapy Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Tumor Immunotherapy Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Tumor Immunotherapy Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Tumor Immunotherapy Drugs Market Facts & Figures by Country
3.7.1 Latin America Tumor Immunotherapy Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Tumor Immunotherapy Drugs Sales by Country (2020-2031)
3.7.3 Latin America Tumor Immunotherapy Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Tumor Immunotherapy Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Tumor Immunotherapy Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Tumor Immunotherapy Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Tumor Immunotherapy Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Tumor Immunotherapy Drugs Sales by Type (2020-2031)
4.1.1 Global Tumor Immunotherapy Drugs Sales by Type (2020-2025)
4.1.2 Global Tumor Immunotherapy Drugs Sales by Type (2026-2031)
4.1.3 Global Tumor Immunotherapy Drugs Sales Market Share by Type (2020-2031)
4.2 Global Tumor Immunotherapy Drugs Revenue by Type (2020-2031)
4.2.1 Global Tumor Immunotherapy Drugs Revenue by Type (2020-2025)
4.2.2 Global Tumor Immunotherapy Drugs Revenue by Type (2026-2031)
4.2.3 Global Tumor Immunotherapy Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Tumor Immunotherapy Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Tumor Immunotherapy Drugs Sales by Application (2020-2031)
5.1.1 Global Tumor Immunotherapy Drugs Sales by Application (2020-2025)
5.1.2 Global Tumor Immunotherapy Drugs Sales by Application (2026-2031)
5.1.3 Global Tumor Immunotherapy Drugs Sales Market Share by Application (2020-2031)
5.2 Global Tumor Immunotherapy Drugs Revenue by Application (2020-2031)
5.2.1 Global Tumor Immunotherapy Drugs Revenue by Application (2020-2025)
5.2.2 Global Tumor Immunotherapy Drugs Revenue by Application (2026-2031)
5.2.3 Global Tumor Immunotherapy Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Tumor Immunotherapy Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Bristol Myer Squibb
6.1.1 Bristol Myer Squibb Company Information
6.1.2 Bristol Myer Squibb Description and Business Overview
6.1.3 Bristol Myer Squibb Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Bristol Myer Squibb Tumor Immunotherapy Drugs Product Portfolio
6.1.5 Bristol Myer Squibb Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Company Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 AstraZeneca Tumor Immunotherapy Drugs Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Merck
6.3.1 Merck Company Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Merck Tumor Immunotherapy Drugs Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Roche / Genentech
6.4.1 Roche / Genentech Company Information
6.4.2 Roche / Genentech Description and Business Overview
6.4.3 Roche / Genentech Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Roche / Genentech Tumor Immunotherapy Drugs Product Portfolio
6.4.5 Roche / Genentech Recent Developments/Updates
6.5 Ono Pharmaceutical
6.5.1 Ono Pharmaceutical Company Information
6.5.2 Ono Pharmaceutical Description and Business Overview
6.5.3 Ono Pharmaceutical Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Ono Pharmaceutical Tumor Immunotherapy Drugs Product Portfolio
6.5.5 Ono Pharmaceutical Recent Developments/Updates
6.6 Regeneron
6.6.1 Regeneron Company Information
6.6.2 Regeneron Description and Business Overview
6.6.3 Regeneron Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Regeneron Tumor Immunotherapy Drugs Product Portfolio
6.6.5 Regeneron Recent Developments/Updates
6.7 Innovent
6.7.1 Innovent Company Information
6.7.2 Innovent Description and Business Overview
6.7.3 Innovent Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Innovent Tumor Immunotherapy Drugs Product Portfolio
6.7.5 Innovent Recent Developments/Updates
6.8 Hengrui Medicine
6.8.1 Hengrui Medicine Company Information
6.8.2 Hengrui Medicine Description and Business Overview
6.8.3 Hengrui Medicine Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Hengrui Medicine Tumor Immunotherapy Drugs Product Portfolio
6.8.5 Hengrui Medicine Recent Developments/Updates
6.9 Junshi Biosciences
6.9.1 Junshi Biosciences Company Information
6.9.2 Junshi Biosciences Description and Business Overview
6.9.3 Junshi Biosciences Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Junshi Biosciences Tumor Immunotherapy Drugs Product Portfolio
6.9.5 Junshi Biosciences Recent Developments/Updates
6.10 Pfizer, Inc
6.10.1 Pfizer, Inc Company Information
6.10.2 Pfizer, Inc Description and Business Overview
6.10.3 Pfizer, Inc Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Pfizer, Inc Tumor Immunotherapy Drugs Product Portfolio
6.10.5 Pfizer, Inc Recent Developments/Updates
6.11 F. Hoffmann-La Roche Ltd
6.11.1 F. Hoffmann-La Roche Ltd Company Information
6.11.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.11.3 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product Portfolio
6.11.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.12 Incyte Corporation
6.12.1 Incyte Corporation Company Information
6.12.2 Incyte Corporation Description and Business Overview
6.12.3 Incyte Corporation Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Incyte Corporation Tumor Immunotherapy Drugs Product Portfolio
6.12.5 Incyte Corporation Recent Developments/Updates
6.13 NewLink Genetics Corporation
6.13.1 NewLink Genetics Corporation Company Information
6.13.2 NewLink Genetics Corporation Description and Business Overview
6.13.3 NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 NewLink Genetics Corporation Tumor Immunotherapy Drugs Product Portfolio
6.13.5 NewLink Genetics Corporation Recent Developments/Updates
6.14 Celldex Therapeutics, Inc
6.14.1 Celldex Therapeutics, Inc Company Information
6.14.2 Celldex Therapeutics, Inc Description and Business Overview
6.14.3 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product Portfolio
6.14.5 Celldex Therapeutics, Inc Recent Developments/Updates
6.15 GlaxoSmithKline
6.15.1 GlaxoSmithKline Company Information
6.15.2 GlaxoSmithKline Description and Business Overview
6.15.3 GlaxoSmithKline Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.15.4 GlaxoSmithKline Tumor Immunotherapy Drugs Product Portfolio
6.15.5 GlaxoSmithKline Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Tumor Immunotherapy Drugs Industry Chain Analysis
7.2 Tumor Immunotherapy Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Tumor Immunotherapy Drugs Production Mode & Process Analysis
7.4 Tumor Immunotherapy Drugs Sales and Marketing
7.4.1 Tumor Immunotherapy Drugs Sales Channels
7.4.2 Tumor Immunotherapy Drugs Distributors
7.5 Tumor Immunotherapy Drugs Customer Analysis
8 Tumor Immunotherapy Drugs Market Dynamics
8.1 Tumor Immunotherapy Drugs Industry Trends
8.2 Tumor Immunotherapy Drugs Market Drivers
8.3 Tumor Immunotherapy Drugs Market Challenges
8.4 Tumor Immunotherapy Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Tumor Immunotherapy Drugs by Type
1.2.1 Global Tumor Immunotherapy Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Tumor Vaccine
1.2.4 Adoptive Immunotherapy
1.2.5 Non-specific Immunomodulator
1.3 Tumor Immunotherapy Drugs by Application
1.3.1 Global Tumor Immunotherapy Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Tumor Immunotherapy Drugs Market Size Estimates and Forecasts
1.4.1 Global Tumor Immunotherapy Drugs Revenue 2020-2031
1.4.2 Global Tumor Immunotherapy Drugs Sales 2020-2031
1.4.3 Global Tumor Immunotherapy Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Tumor Immunotherapy Drugs Market Competition by Manufacturers
2.1 Global Tumor Immunotherapy Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Tumor Immunotherapy Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Tumor Immunotherapy Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Tumor Immunotherapy Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Tumor Immunotherapy Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Tumor Immunotherapy Drugs, Product Type & Application
2.7 Global Key Manufacturers of Tumor Immunotherapy Drugs, Date of Enter into This Industry
2.8 Global Tumor Immunotherapy Drugs Market Competitive Situation and Trends
2.8.1 Global Tumor Immunotherapy Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Tumor Immunotherapy Drugs Players Market Share by Revenue
2.8.3 Global Tumor Immunotherapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Tumor Immunotherapy Drugs Market Scenario by Region
3.1 Global Tumor Immunotherapy Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Tumor Immunotherapy Drugs Sales by Region: 2020-2031
3.2.1 Global Tumor Immunotherapy Drugs Sales by Region: 2020-2025
3.2.2 Global Tumor Immunotherapy Drugs Sales by Region: 2026-2031
3.3 Global Tumor Immunotherapy Drugs Revenue by Region: 2020-2031
3.3.1 Global Tumor Immunotherapy Drugs Revenue by Region: 2020-2025
3.3.2 Global Tumor Immunotherapy Drugs Revenue by Region: 2026-2031
3.4 North America Tumor Immunotherapy Drugs Market Facts & Figures by Country
3.4.1 North America Tumor Immunotherapy Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Tumor Immunotherapy Drugs Sales by Country (2020-2031)
3.4.3 North America Tumor Immunotherapy Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Tumor Immunotherapy Drugs Market Facts & Figures by Country
3.5.1 Europe Tumor Immunotherapy Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Tumor Immunotherapy Drugs Sales by Country (2020-2031)
3.5.3 Europe Tumor Immunotherapy Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Tumor Immunotherapy Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Tumor Immunotherapy Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Tumor Immunotherapy Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Tumor Immunotherapy Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Tumor Immunotherapy Drugs Market Facts & Figures by Country
3.7.1 Latin America Tumor Immunotherapy Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Tumor Immunotherapy Drugs Sales by Country (2020-2031)
3.7.3 Latin America Tumor Immunotherapy Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Tumor Immunotherapy Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Tumor Immunotherapy Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Tumor Immunotherapy Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Tumor Immunotherapy Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Tumor Immunotherapy Drugs Sales by Type (2020-2031)
4.1.1 Global Tumor Immunotherapy Drugs Sales by Type (2020-2025)
4.1.2 Global Tumor Immunotherapy Drugs Sales by Type (2026-2031)
4.1.3 Global Tumor Immunotherapy Drugs Sales Market Share by Type (2020-2031)
4.2 Global Tumor Immunotherapy Drugs Revenue by Type (2020-2031)
4.2.1 Global Tumor Immunotherapy Drugs Revenue by Type (2020-2025)
4.2.2 Global Tumor Immunotherapy Drugs Revenue by Type (2026-2031)
4.2.3 Global Tumor Immunotherapy Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Tumor Immunotherapy Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Tumor Immunotherapy Drugs Sales by Application (2020-2031)
5.1.1 Global Tumor Immunotherapy Drugs Sales by Application (2020-2025)
5.1.2 Global Tumor Immunotherapy Drugs Sales by Application (2026-2031)
5.1.3 Global Tumor Immunotherapy Drugs Sales Market Share by Application (2020-2031)
5.2 Global Tumor Immunotherapy Drugs Revenue by Application (2020-2031)
5.2.1 Global Tumor Immunotherapy Drugs Revenue by Application (2020-2025)
5.2.2 Global Tumor Immunotherapy Drugs Revenue by Application (2026-2031)
5.2.3 Global Tumor Immunotherapy Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Tumor Immunotherapy Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Bristol Myer Squibb
6.1.1 Bristol Myer Squibb Company Information
6.1.2 Bristol Myer Squibb Description and Business Overview
6.1.3 Bristol Myer Squibb Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Bristol Myer Squibb Tumor Immunotherapy Drugs Product Portfolio
6.1.5 Bristol Myer Squibb Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Company Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 AstraZeneca Tumor Immunotherapy Drugs Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Merck
6.3.1 Merck Company Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Merck Tumor Immunotherapy Drugs Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Roche / Genentech
6.4.1 Roche / Genentech Company Information
6.4.2 Roche / Genentech Description and Business Overview
6.4.3 Roche / Genentech Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Roche / Genentech Tumor Immunotherapy Drugs Product Portfolio
6.4.5 Roche / Genentech Recent Developments/Updates
6.5 Ono Pharmaceutical
6.5.1 Ono Pharmaceutical Company Information
6.5.2 Ono Pharmaceutical Description and Business Overview
6.5.3 Ono Pharmaceutical Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Ono Pharmaceutical Tumor Immunotherapy Drugs Product Portfolio
6.5.5 Ono Pharmaceutical Recent Developments/Updates
6.6 Regeneron
6.6.1 Regeneron Company Information
6.6.2 Regeneron Description and Business Overview
6.6.3 Regeneron Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Regeneron Tumor Immunotherapy Drugs Product Portfolio
6.6.5 Regeneron Recent Developments/Updates
6.7 Innovent
6.7.1 Innovent Company Information
6.7.2 Innovent Description and Business Overview
6.7.3 Innovent Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Innovent Tumor Immunotherapy Drugs Product Portfolio
6.7.5 Innovent Recent Developments/Updates
6.8 Hengrui Medicine
6.8.1 Hengrui Medicine Company Information
6.8.2 Hengrui Medicine Description and Business Overview
6.8.3 Hengrui Medicine Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Hengrui Medicine Tumor Immunotherapy Drugs Product Portfolio
6.8.5 Hengrui Medicine Recent Developments/Updates
6.9 Junshi Biosciences
6.9.1 Junshi Biosciences Company Information
6.9.2 Junshi Biosciences Description and Business Overview
6.9.3 Junshi Biosciences Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Junshi Biosciences Tumor Immunotherapy Drugs Product Portfolio
6.9.5 Junshi Biosciences Recent Developments/Updates
6.10 Pfizer, Inc
6.10.1 Pfizer, Inc Company Information
6.10.2 Pfizer, Inc Description and Business Overview
6.10.3 Pfizer, Inc Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Pfizer, Inc Tumor Immunotherapy Drugs Product Portfolio
6.10.5 Pfizer, Inc Recent Developments/Updates
6.11 F. Hoffmann-La Roche Ltd
6.11.1 F. Hoffmann-La Roche Ltd Company Information
6.11.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.11.3 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product Portfolio
6.11.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.12 Incyte Corporation
6.12.1 Incyte Corporation Company Information
6.12.2 Incyte Corporation Description and Business Overview
6.12.3 Incyte Corporation Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Incyte Corporation Tumor Immunotherapy Drugs Product Portfolio
6.12.5 Incyte Corporation Recent Developments/Updates
6.13 NewLink Genetics Corporation
6.13.1 NewLink Genetics Corporation Company Information
6.13.2 NewLink Genetics Corporation Description and Business Overview
6.13.3 NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 NewLink Genetics Corporation Tumor Immunotherapy Drugs Product Portfolio
6.13.5 NewLink Genetics Corporation Recent Developments/Updates
6.14 Celldex Therapeutics, Inc
6.14.1 Celldex Therapeutics, Inc Company Information
6.14.2 Celldex Therapeutics, Inc Description and Business Overview
6.14.3 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product Portfolio
6.14.5 Celldex Therapeutics, Inc Recent Developments/Updates
6.15 GlaxoSmithKline
6.15.1 GlaxoSmithKline Company Information
6.15.2 GlaxoSmithKline Description and Business Overview
6.15.3 GlaxoSmithKline Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.15.4 GlaxoSmithKline Tumor Immunotherapy Drugs Product Portfolio
6.15.5 GlaxoSmithKline Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Tumor Immunotherapy Drugs Industry Chain Analysis
7.2 Tumor Immunotherapy Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Tumor Immunotherapy Drugs Production Mode & Process Analysis
7.4 Tumor Immunotherapy Drugs Sales and Marketing
7.4.1 Tumor Immunotherapy Drugs Sales Channels
7.4.2 Tumor Immunotherapy Drugs Distributors
7.5 Tumor Immunotherapy Drugs Customer Analysis
8 Tumor Immunotherapy Drugs Market Dynamics
8.1 Tumor Immunotherapy Drugs Industry Trends
8.2 Tumor Immunotherapy Drugs Market Drivers
8.3 Tumor Immunotherapy Drugs Market Challenges
8.4 Tumor Immunotherapy Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Tumor Immunotherapy Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Tumor Immunotherapy Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Tumor Immunotherapy Drugs Market Competitive Situation by Manufacturers in 2024
Table 4. Global Tumor Immunotherapy Drugs Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Tumor Immunotherapy Drugs Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Tumor Immunotherapy Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Tumor Immunotherapy Drugs Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Tumor Immunotherapy Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Tumor Immunotherapy Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Tumor Immunotherapy Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Tumor Immunotherapy Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Tumor Immunotherapy Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Tumor Immunotherapy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunotherapy Drugs as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Tumor Immunotherapy Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Tumor Immunotherapy Drugs Sales by Region (2020-2025) & (K Units)
Table 18. Global Tumor Immunotherapy Drugs Sales Market Share by Region (2020-2025)
Table 19. Global Tumor Immunotherapy Drugs Sales by Region (2026-2031) & (K Units)
Table 20. Global Tumor Immunotherapy Drugs Sales Market Share by Region (2026-2031)
Table 21. Global Tumor Immunotherapy Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Tumor Immunotherapy Drugs Revenue Market Share by Region (2020-2025)
Table 23. Global Tumor Immunotherapy Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Tumor Immunotherapy Drugs Revenue Market Share by Region (2026-2031)
Table 25. North America Tumor Immunotherapy Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Tumor Immunotherapy Drugs Sales by Country (2020-2025) & (K Units)
Table 27. North America Tumor Immunotherapy Drugs Sales by Country (2026-2031) & (K Units)
Table 28. North America Tumor Immunotherapy Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Tumor Immunotherapy Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Tumor Immunotherapy Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Tumor Immunotherapy Drugs Sales by Country (2020-2025) & (K Units)
Table 32. Europe Tumor Immunotherapy Drugs Sales by Country (2026-2031) & (K Units)
Table 33. Europe Tumor Immunotherapy Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Tumor Immunotherapy Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Tumor Immunotherapy Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Tumor Immunotherapy Drugs Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Tumor Immunotherapy Drugs Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Tumor Immunotherapy Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Tumor Immunotherapy Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Tumor Immunotherapy Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Tumor Immunotherapy Drugs Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Tumor Immunotherapy Drugs Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Tumor Immunotherapy Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Tumor Immunotherapy Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Tumor Immunotherapy Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Tumor Immunotherapy Drugs Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Tumor Immunotherapy Drugs Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Tumor Immunotherapy Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Tumor Immunotherapy Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Tumor Immunotherapy Drugs Sales (K Units) by Type (2020-2025)
Table 51. Global Tumor Immunotherapy Drugs Sales (K Units) by Type (2026-2031)
Table 52. Global Tumor Immunotherapy Drugs Sales Market Share by Type (2020-2025)
Table 53. Global Tumor Immunotherapy Drugs Sales Market Share by Type (2026-2031)
Table 54. Global Tumor Immunotherapy Drugs Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Tumor Immunotherapy Drugs Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Tumor Immunotherapy Drugs Revenue Market Share by Type (2020-2025)
Table 57. Global Tumor Immunotherapy Drugs Revenue Market Share by Type (2026-2031)
Table 58. Global Tumor Immunotherapy Drugs Price (US$/Unit) by Type (2020-2025)
Table 59. Global Tumor Immunotherapy Drugs Price (US$/Unit) by Type (2026-2031)
Table 60. Global Tumor Immunotherapy Drugs Sales (K Units) by Application (2020-2025)
Table 61. Global Tumor Immunotherapy Drugs Sales (K Units) by Application (2026-2031)
Table 62. Global Tumor Immunotherapy Drugs Sales Market Share by Application (2020-2025)
Table 63. Global Tumor Immunotherapy Drugs Sales Market Share by Application (2026-2031)
Table 64. Global Tumor Immunotherapy Drugs Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Tumor Immunotherapy Drugs Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Tumor Immunotherapy Drugs Revenue Market Share by Application (2020-2025)
Table 67. Global Tumor Immunotherapy Drugs Revenue Market Share by Application (2026-2031)
Table 68. Global Tumor Immunotherapy Drugs Price (US$/Unit) by Application (2020-2025)
Table 69. Global Tumor Immunotherapy Drugs Price (US$/Unit) by Application (2026-2031)
Table 70. Bristol Myer Squibb Company Information
Table 71. Bristol Myer Squibb Description and Business Overview
Table 72. Bristol Myer Squibb Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Bristol Myer Squibb Tumor Immunotherapy Drugs Product
Table 74. Bristol Myer Squibb Recent Developments/Updates
Table 75. AstraZeneca Company Information
Table 76. AstraZeneca Description and Business Overview
Table 77. AstraZeneca Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. AstraZeneca Tumor Immunotherapy Drugs Product
Table 79. AstraZeneca Recent Developments/Updates
Table 80. Merck Company Information
Table 81. Merck Description and Business Overview
Table 82. Merck Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Merck Tumor Immunotherapy Drugs Product
Table 84. Merck Recent Developments/Updates
Table 85. Roche / Genentech Company Information
Table 86. Roche / Genentech Description and Business Overview
Table 87. Roche / Genentech Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Roche / Genentech Tumor Immunotherapy Drugs Product
Table 89. Roche / Genentech Recent Developments/Updates
Table 90. Ono Pharmaceutical Company Information
Table 91. Ono Pharmaceutical Description and Business Overview
Table 92. Ono Pharmaceutical Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Ono Pharmaceutical Tumor Immunotherapy Drugs Product
Table 94. Ono Pharmaceutical Recent Developments/Updates
Table 95. Regeneron Company Information
Table 96. Regeneron Description and Business Overview
Table 97. Regeneron Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Regeneron Tumor Immunotherapy Drugs Product
Table 99. Regeneron Recent Developments/Updates
Table 100. Innovent Company Information
Table 101. Innovent Description and Business Overview
Table 102. Innovent Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Innovent Tumor Immunotherapy Drugs Product
Table 104. Innovent Recent Developments/Updates
Table 105. Hengrui Medicine Company Information
Table 106. Hengrui Medicine Description and Business Overview
Table 107. Hengrui Medicine Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Hengrui Medicine Tumor Immunotherapy Drugs Product
Table 109. Hengrui Medicine Recent Developments/Updates
Table 110. Junshi Biosciences Company Information
Table 111. Junshi Biosciences Description and Business Overview
Table 112. Junshi Biosciences Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Junshi Biosciences Tumor Immunotherapy Drugs Product
Table 114. Junshi Biosciences Recent Developments/Updates
Table 115. Pfizer, Inc Company Information
Table 116. Pfizer, Inc Description and Business Overview
Table 117. Pfizer, Inc Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Pfizer, Inc Tumor Immunotherapy Drugs Product
Table 119. Pfizer, Inc Recent Developments/Updates
Table 120. F. Hoffmann-La Roche Ltd Company Information
Table 121. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 122. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product
Table 124. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 125. Incyte Corporation Company Information
Table 126. Incyte Corporation Description and Business Overview
Table 127. Incyte Corporation Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Incyte Corporation Tumor Immunotherapy Drugs Product
Table 129. Incyte Corporation Recent Developments/Updates
Table 130. NewLink Genetics Corporation Company Information
Table 131. NewLink Genetics Corporation Description and Business Overview
Table 132. NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. NewLink Genetics Corporation Tumor Immunotherapy Drugs Product
Table 134. NewLink Genetics Corporation Recent Developments/Updates
Table 135. Celldex Therapeutics, Inc Company Information
Table 136. Celldex Therapeutics, Inc Description and Business Overview
Table 137. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product
Table 139. Celldex Therapeutics, Inc Recent Developments/Updates
Table 140. GlaxoSmithKline Company Information
Table 141. GlaxoSmithKline Description and Business Overview
Table 142. GlaxoSmithKline Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. GlaxoSmithKline Tumor Immunotherapy Drugs Product
Table 144. GlaxoSmithKline Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Tumor Immunotherapy Drugs Distributors List
Table 148. Tumor Immunotherapy Drugs Customers List
Table 149. Tumor Immunotherapy Drugs Market Trends
Table 150. Tumor Immunotherapy Drugs Market Drivers
Table 151. Tumor Immunotherapy Drugs Market Challenges
Table 152. Tumor Immunotherapy Drugs Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
Table 156. Authors List of This Report
List of Figures
Figure 1. Product Picture of Tumor Immunotherapy Drugs
Figure 2. Global Tumor Immunotherapy Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Tumor Immunotherapy Drugs Market Share by Type: 2024 & 2031
Figure 4. Immune Checkpoint Inhibitors Product Picture
Figure 5. Tumor Vaccine Product Picture
Figure 6. Adoptive Immunotherapy Product Picture
Figure 7. Non-specific Immunomodulator Product Picture
Figure 8. Global Tumor Immunotherapy Drugs Market Value by Application (2020-2031) & (US$ Million)
Figure 9. Global Tumor Immunotherapy Drugs Market Share by Application: 2024 & 2031
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Other
Figure 13. Global Tumor Immunotherapy Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Tumor Immunotherapy Drugs Market Size (2020-2031) & (US$ Million)
Figure 15. Global Tumor Immunotherapy Drugs Sales (2020-2031) & (K Units)
Figure 16. Global Tumor Immunotherapy Drugs Average Price (US$/Unit) & (2020-2031)
Figure 17. Tumor Immunotherapy Drugs Report Years Considered
Figure 18. Tumor Immunotherapy Drugs Sales Share by Manufacturers in 2024
Figure 19. Global Tumor Immunotherapy Drugs Revenue Share by Manufacturers in 2024
Figure 20. Global 5 and 10 Largest Tumor Immunotherapy Drugs Players: Market Share by Revenue in Tumor Immunotherapy Drugs in 2024
Figure 21. Tumor Immunotherapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Global Tumor Immunotherapy Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 23. North America Tumor Immunotherapy Drugs Sales Market Share by Country (2020-2031)
Figure 24. North America Tumor Immunotherapy Drugs Revenue Market Share by Country (2020-2031)
Figure 25. United States Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Canada Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Europe Tumor Immunotherapy Drugs Sales Market Share by Country (2020-2031)
Figure 28. Europe Tumor Immunotherapy Drugs Revenue Market Share by Country (2020-2031)
Figure 29. Germany Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. France Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. U.K. Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Italy Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Russia Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Asia Pacific Tumor Immunotherapy Drugs Sales Market Share by Region (2020-2031)
Figure 35. Asia Pacific Tumor Immunotherapy Drugs Revenue Market Share by Region (2020-2031)
Figure 36. China Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Japan Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. South Korea Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. India Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Australia Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. China Taiwan Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Southeast Asia Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Latin America Tumor Immunotherapy Drugs Sales Market Share by Country (2020-2031)
Figure 44. Latin America Tumor Immunotherapy Drugs Revenue Market Share by Country (2020-2031)
Figure 45. Mexico Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Brazil Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Argentina Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Middle East and Africa Tumor Immunotherapy Drugs Sales Market Share by Country (2020-2031)
Figure 49. Middle East and Africa Tumor Immunotherapy Drugs Revenue Market Share by Country (2020-2031)
Figure 50. Turkey Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. UAE Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Global Sales Market Share of Tumor Immunotherapy Drugs by Type (2020-2031)
Figure 54. Global Revenue Market Share of Tumor Immunotherapy Drugs by Type (2020-2031)
Figure 55. Global Tumor Immunotherapy Drugs Price (US$/Unit) by Type (2020-2031)
Figure 56. Global Sales Market Share of Tumor Immunotherapy Drugs by Application (2020-2031)
Figure 57. Global Revenue Market Share of Tumor Immunotherapy Drugs by Application (2020-2031)
Figure 58. Global Tumor Immunotherapy Drugs Price (US$/Unit) by Application (2020-2031)
Figure 59. Tumor Immunotherapy Drugs Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Global Tumor Immunotherapy Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Tumor Immunotherapy Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Tumor Immunotherapy Drugs Market Competitive Situation by Manufacturers in 2024
Table 4. Global Tumor Immunotherapy Drugs Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Tumor Immunotherapy Drugs Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Tumor Immunotherapy Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Tumor Immunotherapy Drugs Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Tumor Immunotherapy Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Tumor Immunotherapy Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Tumor Immunotherapy Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Tumor Immunotherapy Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Tumor Immunotherapy Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Tumor Immunotherapy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunotherapy Drugs as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Tumor Immunotherapy Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Tumor Immunotherapy Drugs Sales by Region (2020-2025) & (K Units)
Table 18. Global Tumor Immunotherapy Drugs Sales Market Share by Region (2020-2025)
Table 19. Global Tumor Immunotherapy Drugs Sales by Region (2026-2031) & (K Units)
Table 20. Global Tumor Immunotherapy Drugs Sales Market Share by Region (2026-2031)
Table 21. Global Tumor Immunotherapy Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Tumor Immunotherapy Drugs Revenue Market Share by Region (2020-2025)
Table 23. Global Tumor Immunotherapy Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Tumor Immunotherapy Drugs Revenue Market Share by Region (2026-2031)
Table 25. North America Tumor Immunotherapy Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Tumor Immunotherapy Drugs Sales by Country (2020-2025) & (K Units)
Table 27. North America Tumor Immunotherapy Drugs Sales by Country (2026-2031) & (K Units)
Table 28. North America Tumor Immunotherapy Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Tumor Immunotherapy Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Tumor Immunotherapy Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Tumor Immunotherapy Drugs Sales by Country (2020-2025) & (K Units)
Table 32. Europe Tumor Immunotherapy Drugs Sales by Country (2026-2031) & (K Units)
Table 33. Europe Tumor Immunotherapy Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Tumor Immunotherapy Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Tumor Immunotherapy Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Tumor Immunotherapy Drugs Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Tumor Immunotherapy Drugs Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Tumor Immunotherapy Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Tumor Immunotherapy Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Tumor Immunotherapy Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Tumor Immunotherapy Drugs Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Tumor Immunotherapy Drugs Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Tumor Immunotherapy Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Tumor Immunotherapy Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Tumor Immunotherapy Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Tumor Immunotherapy Drugs Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Tumor Immunotherapy Drugs Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Tumor Immunotherapy Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Tumor Immunotherapy Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Tumor Immunotherapy Drugs Sales (K Units) by Type (2020-2025)
Table 51. Global Tumor Immunotherapy Drugs Sales (K Units) by Type (2026-2031)
Table 52. Global Tumor Immunotherapy Drugs Sales Market Share by Type (2020-2025)
Table 53. Global Tumor Immunotherapy Drugs Sales Market Share by Type (2026-2031)
Table 54. Global Tumor Immunotherapy Drugs Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Tumor Immunotherapy Drugs Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Tumor Immunotherapy Drugs Revenue Market Share by Type (2020-2025)
Table 57. Global Tumor Immunotherapy Drugs Revenue Market Share by Type (2026-2031)
Table 58. Global Tumor Immunotherapy Drugs Price (US$/Unit) by Type (2020-2025)
Table 59. Global Tumor Immunotherapy Drugs Price (US$/Unit) by Type (2026-2031)
Table 60. Global Tumor Immunotherapy Drugs Sales (K Units) by Application (2020-2025)
Table 61. Global Tumor Immunotherapy Drugs Sales (K Units) by Application (2026-2031)
Table 62. Global Tumor Immunotherapy Drugs Sales Market Share by Application (2020-2025)
Table 63. Global Tumor Immunotherapy Drugs Sales Market Share by Application (2026-2031)
Table 64. Global Tumor Immunotherapy Drugs Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Tumor Immunotherapy Drugs Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Tumor Immunotherapy Drugs Revenue Market Share by Application (2020-2025)
Table 67. Global Tumor Immunotherapy Drugs Revenue Market Share by Application (2026-2031)
Table 68. Global Tumor Immunotherapy Drugs Price (US$/Unit) by Application (2020-2025)
Table 69. Global Tumor Immunotherapy Drugs Price (US$/Unit) by Application (2026-2031)
Table 70. Bristol Myer Squibb Company Information
Table 71. Bristol Myer Squibb Description and Business Overview
Table 72. Bristol Myer Squibb Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Bristol Myer Squibb Tumor Immunotherapy Drugs Product
Table 74. Bristol Myer Squibb Recent Developments/Updates
Table 75. AstraZeneca Company Information
Table 76. AstraZeneca Description and Business Overview
Table 77. AstraZeneca Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. AstraZeneca Tumor Immunotherapy Drugs Product
Table 79. AstraZeneca Recent Developments/Updates
Table 80. Merck Company Information
Table 81. Merck Description and Business Overview
Table 82. Merck Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Merck Tumor Immunotherapy Drugs Product
Table 84. Merck Recent Developments/Updates
Table 85. Roche / Genentech Company Information
Table 86. Roche / Genentech Description and Business Overview
Table 87. Roche / Genentech Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Roche / Genentech Tumor Immunotherapy Drugs Product
Table 89. Roche / Genentech Recent Developments/Updates
Table 90. Ono Pharmaceutical Company Information
Table 91. Ono Pharmaceutical Description and Business Overview
Table 92. Ono Pharmaceutical Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Ono Pharmaceutical Tumor Immunotherapy Drugs Product
Table 94. Ono Pharmaceutical Recent Developments/Updates
Table 95. Regeneron Company Information
Table 96. Regeneron Description and Business Overview
Table 97. Regeneron Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Regeneron Tumor Immunotherapy Drugs Product
Table 99. Regeneron Recent Developments/Updates
Table 100. Innovent Company Information
Table 101. Innovent Description and Business Overview
Table 102. Innovent Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Innovent Tumor Immunotherapy Drugs Product
Table 104. Innovent Recent Developments/Updates
Table 105. Hengrui Medicine Company Information
Table 106. Hengrui Medicine Description and Business Overview
Table 107. Hengrui Medicine Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Hengrui Medicine Tumor Immunotherapy Drugs Product
Table 109. Hengrui Medicine Recent Developments/Updates
Table 110. Junshi Biosciences Company Information
Table 111. Junshi Biosciences Description and Business Overview
Table 112. Junshi Biosciences Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Junshi Biosciences Tumor Immunotherapy Drugs Product
Table 114. Junshi Biosciences Recent Developments/Updates
Table 115. Pfizer, Inc Company Information
Table 116. Pfizer, Inc Description and Business Overview
Table 117. Pfizer, Inc Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Pfizer, Inc Tumor Immunotherapy Drugs Product
Table 119. Pfizer, Inc Recent Developments/Updates
Table 120. F. Hoffmann-La Roche Ltd Company Information
Table 121. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 122. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product
Table 124. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 125. Incyte Corporation Company Information
Table 126. Incyte Corporation Description and Business Overview
Table 127. Incyte Corporation Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Incyte Corporation Tumor Immunotherapy Drugs Product
Table 129. Incyte Corporation Recent Developments/Updates
Table 130. NewLink Genetics Corporation Company Information
Table 131. NewLink Genetics Corporation Description and Business Overview
Table 132. NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. NewLink Genetics Corporation Tumor Immunotherapy Drugs Product
Table 134. NewLink Genetics Corporation Recent Developments/Updates
Table 135. Celldex Therapeutics, Inc Company Information
Table 136. Celldex Therapeutics, Inc Description and Business Overview
Table 137. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product
Table 139. Celldex Therapeutics, Inc Recent Developments/Updates
Table 140. GlaxoSmithKline Company Information
Table 141. GlaxoSmithKline Description and Business Overview
Table 142. GlaxoSmithKline Tumor Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. GlaxoSmithKline Tumor Immunotherapy Drugs Product
Table 144. GlaxoSmithKline Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Tumor Immunotherapy Drugs Distributors List
Table 148. Tumor Immunotherapy Drugs Customers List
Table 149. Tumor Immunotherapy Drugs Market Trends
Table 150. Tumor Immunotherapy Drugs Market Drivers
Table 151. Tumor Immunotherapy Drugs Market Challenges
Table 152. Tumor Immunotherapy Drugs Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
Table 156. Authors List of This Report
List of Figures
Figure 1. Product Picture of Tumor Immunotherapy Drugs
Figure 2. Global Tumor Immunotherapy Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Tumor Immunotherapy Drugs Market Share by Type: 2024 & 2031
Figure 4. Immune Checkpoint Inhibitors Product Picture
Figure 5. Tumor Vaccine Product Picture
Figure 6. Adoptive Immunotherapy Product Picture
Figure 7. Non-specific Immunomodulator Product Picture
Figure 8. Global Tumor Immunotherapy Drugs Market Value by Application (2020-2031) & (US$ Million)
Figure 9. Global Tumor Immunotherapy Drugs Market Share by Application: 2024 & 2031
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Other
Figure 13. Global Tumor Immunotherapy Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Tumor Immunotherapy Drugs Market Size (2020-2031) & (US$ Million)
Figure 15. Global Tumor Immunotherapy Drugs Sales (2020-2031) & (K Units)
Figure 16. Global Tumor Immunotherapy Drugs Average Price (US$/Unit) & (2020-2031)
Figure 17. Tumor Immunotherapy Drugs Report Years Considered
Figure 18. Tumor Immunotherapy Drugs Sales Share by Manufacturers in 2024
Figure 19. Global Tumor Immunotherapy Drugs Revenue Share by Manufacturers in 2024
Figure 20. Global 5 and 10 Largest Tumor Immunotherapy Drugs Players: Market Share by Revenue in Tumor Immunotherapy Drugs in 2024
Figure 21. Tumor Immunotherapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Global Tumor Immunotherapy Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 23. North America Tumor Immunotherapy Drugs Sales Market Share by Country (2020-2031)
Figure 24. North America Tumor Immunotherapy Drugs Revenue Market Share by Country (2020-2031)
Figure 25. United States Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Canada Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Europe Tumor Immunotherapy Drugs Sales Market Share by Country (2020-2031)
Figure 28. Europe Tumor Immunotherapy Drugs Revenue Market Share by Country (2020-2031)
Figure 29. Germany Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. France Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. U.K. Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Italy Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Russia Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Asia Pacific Tumor Immunotherapy Drugs Sales Market Share by Region (2020-2031)
Figure 35. Asia Pacific Tumor Immunotherapy Drugs Revenue Market Share by Region (2020-2031)
Figure 36. China Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Japan Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. South Korea Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. India Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Australia Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. China Taiwan Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Southeast Asia Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Latin America Tumor Immunotherapy Drugs Sales Market Share by Country (2020-2031)
Figure 44. Latin America Tumor Immunotherapy Drugs Revenue Market Share by Country (2020-2031)
Figure 45. Mexico Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Brazil Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Argentina Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Middle East and Africa Tumor Immunotherapy Drugs Sales Market Share by Country (2020-2031)
Figure 49. Middle East and Africa Tumor Immunotherapy Drugs Revenue Market Share by Country (2020-2031)
Figure 50. Turkey Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. UAE Tumor Immunotherapy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Global Sales Market Share of Tumor Immunotherapy Drugs by Type (2020-2031)
Figure 54. Global Revenue Market Share of Tumor Immunotherapy Drugs by Type (2020-2031)
Figure 55. Global Tumor Immunotherapy Drugs Price (US$/Unit) by Type (2020-2031)
Figure 56. Global Sales Market Share of Tumor Immunotherapy Drugs by Application (2020-2031)
Figure 57. Global Revenue Market Share of Tumor Immunotherapy Drugs by Application (2020-2031)
Figure 58. Global Tumor Immunotherapy Drugs Price (US$/Unit) by Application (2020-2031)
Figure 59. Tumor Immunotherapy Drugs Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Trichosanthes Kirilowii Extract Market Research Report 2026
Feb 24, 26
Global Glass Lined Containers Market Research Report 2026
Feb 24, 26
Global Open End Wrenches Market Research Report 2026
Feb 24, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232